Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Pentax Medical, a division of HOYA Corporation, stands as a global leader in the medical, precision, and optical instruments industry. Headquartered in Japan, with significant operations worldwide, the company is renowned for its advanced endo-imaging devices and solutions.
Founded in 1919 as Asahi Optical Joint Stock Co., Pentax Medical has a rich history of innovation. Its expertise lies in developing and manufacturing cutting-edge endoscopy equipment, including endoscopes, processors, and therapeutic devices.
These instruments are vital for diagnostic and therapeutic procedures in gastroenterology, pulmonology, and urology. Pentax Medical's commitment to delivering high-quality, innovative technology aims to enhance clinical outcomes and improve patient care globally.
31
DitchCarbon score
-1 vs industry average
Pentax Medical’s score of 31 is lower than 49% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Pentax Medical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
High
Medical Device Manufacturing has above-average carbon intensity
Industry performance
0.308
20182025
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Pentax Medical's reported carbon emissions
Pentax Medical, headquartered in Japan within the Medical, precision and optical instruments, watches and clocks industry, reported its most recent carbon emissions data for 2024. The company's Scope 1 emissions, primarily from stationary combustion, were 5,900,000 kg CO2e. Scope 2 emissions, attributed to purchased electricity, amounted to 4,410,000 kg CO2e. Scope 3 emissions, largely from purchased goods and services, were significantly higher at 89,600,000 kg CO2e.
Pentax Medical inherits its SBTi, CDP, and RE100 initiative data from its ultimate parent company, HOYA Corporation. While specific reduction targets for Pentax Medical are not disclosed, this cascading relationship indicates an alignment with broader corporate climate strategies.
Assessing Pentax Medical as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Pentax Medical and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Pentax Medical’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Pentax Medical yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Inherited from HOYA CorporationSee details
Active
Carbon Disclosure Project
Inherited from HOYA CorporationSign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
Inherited from HOYA CorporationSee details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Pentax Medical13 days ago
31
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more